Found 216 articles
Generex Biotechnology Appoints Independent Directors Craig Eagle, MD and Thomas Leonard to the NuGenerex Immuno-Oncology Board of Directors
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointments of Dr. Craig Eagle, MD and Mr. Thomas Leonard to the NuGenerex Immuno-Oncology (NGIO) Board of Directors.
PhoreMost to deploy its SITESEEKER platform to identify novel targets for Boehringer Ingelheim's discovery programmes
Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma
Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced interim results from its Phase 1b clinical trial of a topical ocular formulation of AKB-9778 in development as a potential treatment for primary open angle glaucoma (POAG).
Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. IDE Trial for iStent infinite™
Company Completes Enrollment of Subjects in Trial Designed to Evaluate Safety and Performance of Its Three-Stent System in Standalone Procedure for Advanced Glaucoma
FASENRA® (benralizumab) Approved in the US for Self-administration in a New Pre-filled Auto-injector, the FASENRA Pen™
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the self-administration of FASENRA® (benralizumab) in a pre-filled, single-use auto-injector (the FASENRA Pen™).
The campaign was made possible by funding from Health Canada, encouraging young adults to follow the misguided adventures of a not-so-superhero called "The Toker"
7/17/2019A federal judge ordered that information on sales of opioids up to the year 2013 could be released.
Board appointment will help guide target identification and drug discovery
inStem’s Centre for Chemical Biology and Therapeutics to work with PhoreMost to progress selected targets
C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today entered into a collaboration with PhoreMost, a UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets
Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target
Ligand will now apply its Vernalis Design Platform (VDP) to design small molecule inhibitors against the target, to help rapidly progress compounds through hit-to-lead and lead optimization stages.
First anti-IL5 biologic to give healthcare professionals choice of how and where their patients receive treatment
Here's a roundup of some of the top clinical trial news from the previous week.
FASENRA® (benralizumab) reduces oral corticosteroid use and maintains long-term efficacy and safety profile in severe eosinophilic asthma
Integrated analysis of a large cohort of continuously treated patients to be presented at American Thoracic Society 2019 International Conference
The 96-Week data showed continued efficacy of GS010 two years after injection, with best-corrected visual acuity (BCVA) holding a clinically meaningful improvement over baseline.
GenSight Biologics Reports Positive 96-Week Data from REVERSE Phase III Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON)
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported a first set of results from Week 96 of the REVERSE Phase III clinical trial.
GenSight Biologics Reports Positive Follow-up Results at Week 72 of the RESCUE Phase III Clinical Trial of GS010 in Leber Hereditary Optic Neuropathy (LHON)
GS010-treated eyes showed continuous recovery of visual functions from nadir (worst vision post-treatment) in both best-corrected visual acuity (BCVA) and contrast sensitivity (CS)
Inspirational New Documentary 'UnMASKing HOPE' to Feature Extraordinary Stories of Trauma Survivors on Journeys to Find Hope - from Acclaimed Filmmaker Eric Christiansen
Acclaimed documentary writer/director/producer Eric Christiansen has announced production for his next full-length documentary, UnMASKing HOPE and the release of the film's official trailer.
- NHS-approved PARP inhibitor therapy found to boost the body’s immune response - Drugs could be used to increase number of patients who respond to immunotherapies - Treatment developed for ovarian and breast cancers could also work in some lung cancers
Wize Pharma, Inc. Announces Publication of Peer Reviewed LOA2 Data on Treatment of Moderately Severe Sjögren's Syndrome-Related Dry Eye
Data shows statistically significant improvement after 3 months of treatment in both objective and subjective measures